PMH55 CANADIAN COST-EFFECTIVENESS ANALYSIS OF LONG-ACTING RISPERIDONE VERSUS ORAL ATYPICAL AND CONVENTIONAL DEPOT ANTIPSYCHOTICS IN PATIENTS WITH SCHIZOPHRENIA AT HIGH-RISK OF NON-COMPLIANCE- UPDATED BASED ON NEW CLINICAL DATA
May 1, 2010, 00:00
10.1016/S1098-3015(10)72550-X
https://www.valueinhealthjournal.com/article/S1098-3015(10)72550-X/fulltext
Title :
PMH55 CANADIAN COST-EFFECTIVENESS ANALYSIS OF LONG-ACTING RISPERIDONE VERSUS ORAL ATYPICAL AND CONVENTIONAL DEPOT ANTIPSYCHOTICS IN PATIENTS WITH SCHIZOPHRENIA AT HIGH-RISK OF NON-COMPLIANCE- UPDATED BASED ON NEW CLINICAL DATA
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)72550-X&doi=10.1016/S1098-3015(10)72550-X
First page :
Section Title :
Open access? :
No
Section Order :
87